NeoGraph Analytics
Healthcare TechnologyNorth America20232032

US AI In Oncology Market Size, Share and Trends Analysis

The US AI in Oncology market reached $1.8 billion in 2023 and is projected to grow at a 28.5% CAGR, reaching $15.1 billion by 2032. Explore key trends, segmentations, and leading players.

Revenue, 2023

$1.8B

Forecast, 2032

$15.1B

CAGR, 2024-2032

28.5%

Report Coverage

North America

Code: us-ai-in-oncology-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The US AI in Oncology market is experiencing rapid growth with a current valuation of $1.8 billion, driven by advances in machine learning and increasing adoption of precision oncology solutions, projected to reach $15.1 billion by 2032 at a robust 28.5% CAGR.

Market Stage

Early growth

Adoption Level

Growing

Key Trends

Integration of multi-omics data for personalized treatment planningFDA clearance of AI-powered diagnostic imaging toolsShift toward real-world evidence generation through AI platformsIncreased investment in AI-driven clinical trial design
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 28.5%

Base Year (2023)

$2.3B

Forecast (2032)

$15.1B

CAGR (2024-2032)

28.5%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 65.2%CAGR: 29.1%

Largest market: United States

Europe

#2
Share: 25.8%CAGR: 24.7%

Largest market: Germany

03

Market Dynamics

  • Rising cancer incidence rates requiring more efficient diagnostic workflows
  • Regulatory frameworks enabling AI medical device approvals
  • Increasing availability of structured clinical data for algorithm training
  • Demand for cost-effective precision oncology solutions
04

Market Segmentation

By Application

  • Diagnostic Imaging Analysis
  • Treatment Planning & Personalization
  • Drug Discovery & Development
  • Clinical Decision Support

By End User

  • Hospitals & Academic Medical Centers
  • Specialized Oncology Clinics
  • Pharmaceutical Companies
  • Research Institutions
05

Regional Analysis

1

North America

Lead: United States
CAGR: 29.1%Share: 65.2%

Dominates the global market due to advanced healthcare infrastructure, strong venture capital investment, and early adoption of AI technologies in oncology.

2

Europe

Lead: Germany
CAGR: 24.7%Share: 25.8%

Growing market driven by digital health initiatives and strong regulatory frameworks supporting AI in healthcare.

3

Asia Pacific

Lead: China
CAGR: 35.4%Share: 9.0%

Fastest-growing region with significant government investment in AI healthcare solutions and expanding oncology care infrastructure.

Country-Level Analysis

CountryShareGrowth
United States
65.2%
+29.1%
Germany
12.3%
+24.1%
China
8.7%
+35.4%
United Kingdom
6.9%
+22.8%
06

Competitive Landscape

P

PathAI

Boston, USA

Leader120M

Specializes in AI-powered pathology solutions for cancer diagnosis and treatment response prediction

PathAI Diagnostic PlatformPathAI Oncology Suite
T

Tempus

Chicago, USA

Challenger450M

Develops AI platforms integrating genomic and clinical data for precision oncology

Tempus AI PlatformTempus Clinical Analytics
I

IBM Watson Health

Armonk, USA

Follower6.2B

Offers AI solutions for oncology treatment planning and clinical trial matching

IBM Watson OncologyIBM Watson for Clinical Trial Matching
E

Enlitic

San Francisco, USA

Challenger

Provides AI-powered medical imaging solutions for cancer detection

O

Oncora Medical

Boston, USA

Niche Player

Focuses on AI-driven treatment planning for radiation oncology

07

Recent Developments

25
2025IBM Watson Health

Launch of new AI module for predicting immunotherapy response in melanoma

25
2025Oncora Medical

FDA clearance for AI-driven radiation therapy planning solution

24
2024PathAI

FDA clearance for AI-powered breast cancer diagnosis platform

24
2024Tempus

Partnership with Mayo Clinic for AI-driven treatment planning in lung cancer

24
2024Enlitic

Integration of AI with cloud-based imaging platforms for radiology workflow optimization

08

Regulatory Landscape

FDA's AI/ML Software as a Medical Device (SaMD) frameworkHIPAA regulations for healthcare data privacyEU Medical Device Regulation (MDR) for AI-based oncology toolsGDPR compliance requirements for patient data processing
09

Frequently Asked Questions

The US AI in Oncology market was valued at $1.8 billion in 2023.
The market is projected to grow at a CAGR of 28.5% from 2024 to 2032.
Diagnostic Imaging Analysis represents the largest segment with 42.5% market share.
PathAI holds the leadership position in the US AI Oncology market.